Squamous cell carcinoma (SCC) is a treatment-refractory subtype of human cancer arising from stratified epithelium of the skin, lung, esophagus, oropharynx and other tissues. A unifying feature of SCC is high-level expression of the p53-related protein p63 (TP63) in 80% of cases. The major protein isoform of p63 expressed in SCC is ΔNp63α, an N-terminally truncated form which functions as a key SCC cell survival factor by mechanisms that are unclear. In this study we demonstrate that ΔNp63α associates with HDAC1 and HDAC2 to form an active transcriptional repressor complex that can be targeted to therapeutic advantage. Repression of pro-apoptotic Bcl-2 family member genes including PUMA by p63/HDAC is required for survival of SCC cells. Cisplatin chemotherapy, a mainstay of SCC treatment, promotes dissociation of p63 and HDAC from the PUMA promoter, leading to increased histone acetylation, PUMA activation and apoptosis. These effects are recapitulated upon targeting the p63/HDAC complex selectively with class I/II HDAC inhibitors using both in vitro and in vivo models.
Introduction
Understanding the biochemical basis for tumor maintenance is critical to the rational application of targeted therapeutic agents. In squamous cell carcinoma (SCC), the p53 family member p63 is a key survival factor whose inhibition by RNA interference induces apoptosis, and whose degradation by cisplatin-based chemotherapy is thought to be important for the therapeutic response to this agent (1) (2) (3) (4) . The p63 gene is expressed through two promoters as two distinct isoform classes which either contain (TAp63) or lack (ΔNp63) an N-terminal transactivation domain. Additional isoform heterogeneity is generated through alternative C-terminal splicing (5) . Consistently, the major p63 isoform overexpressed in SCC is ΔNp63α, a protein which has been shown to function as a positive and negative transcriptional regulator of different target gene subsets (5, 6) .
Given its potential therapeutic relevance, precisely how ΔNp63α mediates tumor cell survival is under intensive investigation. We previously demonstrated that ΔNp63α functions in part by binding and suppressing the pro-apoptotic activity of the related p53 family member p73 (1, 7) . Whether binding to p73 is sufficient for tumor cell survival in this setting is unresolved. Additionally, we and others have observed localization of p63 to the promoters of pro-apoptotic Bcl-2 family members including PUMA, raising the possibility that ΔNp63α functions as an active transcriptional repressor (1, 8) . Here, we use biochemical approaches to identify an endogenous repressor complex involving ΔNp63α, HDAC1 and HDAC2, and we demonstrate the potential relevance of p63/HDAC-mediated transcriptional repression in the response to cisplatin chemotherapy and HDAC inhibitor therapy in SCC.
Research. Lentiviral and retroviral production, Luciferase assays, and mRNA QRT-PCR.
Production of virus, luciferase assays, and mRNA analysis were performed as described (1) . Primers used for QRT-PCR are shown in Table S1 .
Preparation of nuclear extracts and glycerol density gradient fractionation. Nuclear extracts were prepared by suspending cells in hypotonic buffer (10mM Tris-HCl pH 7.5, 1.5mM MgCl 2 , 10mM KCl) for 20 minutes, followed by douncing. Pelleted nuclei were suspended in 1 volume 20mM KCl nuclear buffer (20mM Tris-HCl pH 7.5, 1.5mM
MgCl 2 , 0.2 mM EDTA, 25% glycerol). One volume 1.2M KCl nuclear buffer was added dropwise then incubated for 30 minutes at 4 o C with rotation. Cleared supernatant was dialyzed against BC-100 buffer (100mM KCl, 20mM Tris-HCl pH 7.5, 0.2 mM EDTA, 20% glycerol). Glycerol density gradient fractionation was performed as previously described (12) .
Tandem affinity purification. Cells were stably infected with pMSCV-ΔNp63α-FLAG-HA (C-terminal) or pMSCV-GFP-FLAG-HA plasmids, and cleared lysates from nuclear extracts were incubated for 4 hours with α-FLAG conjugated beads. Beads were washed with 100mM, 250mM, 500mM, 250mM, and 100mM KCl wash buffer (50mM 
Statistics
. P values were determined using the student's unpaired t test unless indicated otherwise. For figure 4B, Pearson's Product-moment Correlation Coefficient (R2) was calculated and a two tailed P-value was generated from a probability table.
Research. 
Results and Discussion

Interaction between endogenous p63 and HDAC1/2.
In order to uncover the biochemical basis for p63-dependent transcriptional regulation, we isolated p63-associated nuclear proteins from JHU-029, a human squamous cell carcinoma (SCC)-derived cell line in which endogenous p63 functions as an essential suppressor of apoptosis (1, 7). Using tandem affinity purification (TAP), we purified complexes from nuclear extracts of cells expressing either ΔNp63α-FLAG/HA or control nuclear GFP-FLAG/HA. Expected p63-associated proteins, including endogenous p63 and p73, were identified on silver-stained gels and subsequently confirmed by mass spectrometry ( Figure 1A ) (1, 14) . The next most abundant silver-stained band, observed consistently following ΔNp63α but not GFP purification, contained HDAC1 and HDAC2 proteins ( Figure 1A ). To confirm the specificity of their interactions with p63, we performed western analysis for HDAC1 and HDAC2 following TAP for tagged ΔNp63α or nuclear GFP control. Consistent with our mass spectrometry findings, endogenous HDAC1 and HDAC2 specifically interacted with ΔNp63α but not with nuclear GFP ( Figure 1A ).
Using glycerol density gradient fractionation, we observed co-fractionation of endogenous ΔNp63α, HDAC1, and HDAC2 in complexes greater than 440kDa, potentially suggesting the presence of a complex involving these three proteins ( Figure   1B ). To confirm the endogenous association we performed reciprocal coimmunoprecipitations for p63, HDAC1 and HDAC2 in JHU-029 cells ( Figure 1C ) and a second HNSCC line, FaDU ( Figure S1A ), and observed a specific interaction between these three proteins. Finally, in order to examine these interactions in more detail we mapped the domain of p63 required for HDAC association. We transfected a series of FLAG-tagged p63 deletion mutants ( Figure S1B ) together with HDAC1 into 293T cells, and performed immunoprecipitations using either α-FLAG ( Figure 1D established association between HDAC1 and HDAC2 (15), our findings collectively suggest that ΔNp63α, HDAC1 and HDAC2 exist in a trimeric complex in SCC cells.
Requirement for p63 promoter association in p63-mediated repression
We hypothesized that p63 mediates direct transcriptional repression in SCC cells through recruitment of HDACs to the promoters of pro-apoptotic genes including PUMA. This hypothesis requires that p63 and HDACs are localized to this promoter, and that promoter binding by p63 is essential for its ability to repress transcription. We therefore performed chromatin immunoprecipitation (ChIP) for p63 and HDAC1 in SCC cells, and observed specific binding of both endogenous proteins to the PUMA locus (Figure 2A) . Binding of p63 and HDAC1 was also observed within the regulatory regions of other p63-repressed genes ( Figure S2A ). To address the functional contribution of promoter binding by ΔNp63α we first used a PUMA promoter reporter assay (1). We co-expressed either wildtype ΔNp63α (WT) or a naturally-occurring DNA binding-deficient point mutant, ΔNp63α (R304W) (5), together with TAp73β or p53 and examined luciferase activity.
Wild-type ΔNp63α was a potent suppressor of both p73 and p53-dependent PUMA reporter activation, while the non-DNA binding mutant ΔNp63α (R304W) was defective in suppressing activation ( Figure 2B ). Of note, the p63 mutant was expressed at similar levels as the wild-type ( Figure 2B ) and exhibits comparable binding to p73 ( Figure S2B) but not to p53 ( Figure S2C ).
Since transient reporter assays lack chromatin context, we next tested whether suppression of endogenous PUMA transcription required DNA-bound p63. We expressed retroviral FLAG-tagged wild-type or mutant ΔNp63α (R304W) in SCC cells, then performed ChIP using an anti-FLAG antibody. As expected, wild-type ΔNp63α showed significant binding to the PUMA promoter, while the mutant showed little or no binding over background ( Figure 2C) . As a functional test we then ablated expression of endogenous p63 in these cells, having engineered the ectopic ΔNp63α constructs to contain silent point mutants which made them resistant to the lentiviral shRNA ( Figure   S2D Figures 2D and S2E ) and cell death ( Figure S2F ) in this setting. Taken together, these data demonstrate the requirement for promoter-bound p63 in suppression of endogenous PUMA transcription and cell death in SCC cells.
HDAC and p63-dependent regulation of PUMA and chemotherapy response in SCC cells
Having documented the presence of endogenous HDAC1 and p63 at the PUMA promoter Cisplatin-based chemotherapy, a mainstay for treatment of advanced head and neck SCC (HNSCC), promotes degradation of ΔNp63α and induction of PUMA which have been linked to the therapeutic response in this disease (3, 4) . We found that disruption of the p63/HDAC complex contributes to the response to cisplatin, as PUMA expression induced by cisplatin ( Figures S3D and S3E ) was accompanied by a loss of endogenous p63 and HDAC1 at the PUMA promoter, and by an increase in histone acetylation ( Figures 3D and S3D) . Thus p63/HDAC-mediated PUMA transcriptional repression is mitigated in the physiological response to cisplatin chemotherapy. 
Targeting p63/HDAC-dependent transcriptional repression in SCC
We have demonstrated previously that some SCC cell lines are able to bypass the requirement for ΔNp63α as a survival factor through overexpression of endogenous Bcl-2 itself (1, 17) . Consistent with this observation, we found that SCC lines which exhibit low expression of ΔNp63α showed high-level expression of Bcl-2, and vice-versa ( Figure 4A and reference (1) ). We therefore hypothesized that lines with high ΔNp63α expression are "addicted" to ΔNp63α/HDAC function and therefore would be sensitive to HDAC inhibition, while lines with low ΔNp63α would exhibit HDAC inhibitor resistance. Indeed, we observed a direct correlation between ΔNp63α protein levels and sensitivity to TSA in SCC cells ( Figures 4B and S4A) . Additionally, we found that ectopic Bcl-2 expression was sufficient to confer remarkable in vitro TSA resistance in the TSA-sensitive line JHU-029 ( Figure S4B ). Thus, although multiple pathways may contribute to effects of HDAC inhibition in SCC cells (18) , these data support a prominent role for the p63-dependent pathway we describe here.
Finally, we sought to model HDAC inhibition for treatment of SCC in vivo and to determine the contribution of Bcl-2 expression in this setting. Notably, we recently showed that Bcl-2 expression in primary HNSCC is an intrinsic resistance factor and a powerful predictor of relapse following cisplatin-based therapy (17) . We established a xenograft assay using JHU-029 cells, which form tumors in 100% of Nude mice when injected subcutaneously. Mice bearing palpable tumors, derived from JHU-029 cells expressing either a retroviral control (GFP) or Bcl-2 vector, were treated by IP injection with vorinostat or vehicle control. Vorinostat treatment substantially and consistently blocked tumor progression in mice with GFP-expressing tumors ( Figure 4C ).
Remarkably, however, expression of Bcl-2 induced complete resistance to vorinostat treatment ( Figure 4C ). To determine the physiological basis for the response to HDAC inhibition in vivo we assayed markers of proliferation and apoptosis in these tumors. We observed no difference in proliferation following vorinostat treatment in any tumors, as assessed by Ki67 staining (Figures S4C,D) . In contrast, control vorinostat-treated tumors showed substantial cleaved PARP-1 ( Figure 4D CAN-11-0046 demonstrate the presence of a functional p63/HDAC complex which serves as a direct repressor of the apoptotic transcriptional program in SCC. HDAC inhibitors target this complex to induce tumor cell killing through up-regulation of pro-apoptotic Bcl-2 family members, while sensitivity to these drugs can be abrogated in tumor cells that overexpress Bcl-2.
These findings reveal a tumor-specific context for HDAC function in SCC which will inform the rational and effective application of these agents. 
